JAAD OnlineComment on “Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up”
References (5)
- et al.
Folliculitis decalvans: effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up
J Am Acad Dermatol
(2018) - et al.
Updates in therapeutics for folliculitis decalvans: a systematic review with evidence-based analysis
J Am Acad Dermatol
(2019)
There are more references available in the full text version of this article.
Cited by (2)
Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology
2020, Anais Brasileiros de DermatologiaCitation Excerpt :Isotretinoin is widely cited, with differences regarding efficacy, safety, time to remission, and relapses.209 In a retrospective study involving 82 patients, 16 (20%) used isotretinoin; eight (50%) improved, but the duration of the response was only three months.210 A multicenter, prospective study included 60 patients with QFD and different treatments; 15 (25%) were treated with isotretinoin for three months, with no difference in efficacy compared with the combination of rifampicin and clindamycin in the five-year follow-up.
Reply to: “Comment on ‘Folliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up’”
2019, Journal of the American Academy of Dermatology
Funding sources: None.
Conflicts of interest: None disclosed.
© 2019 by the American Academy of Dermatology, Inc.